Order Article Reprints

Myint KZ, Balasubramanian B, Venkatraman S, Phimsen S, Sripramote S, Jantra J, Choeiphuk C, Mingphruedhi S, Muangkaew P, Rungsakulkij N, et al. Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation. Pharmaceuticals. 2024; 17(2):197. https://doi.org/10.3390/ph17020197

Myint, Kyaw Zwar, Brinda Balasubramanian, Simran Venkatraman, Suchada Phimsen, Supisara Sripramote, Jeranan Jantra, Chaiwat Choeiphuk, Somkit Mingphruedhi, Paramin Muangkaew, Narongsak Rungsakulkij, and et al. 2024. "Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation" Pharmaceuticals 17, no. 2: 197. https://doi.org/10.3390/ph17020197

Myint, K. Z., Balasubramanian, B., Venkatraman, S., Phimsen, S., Sripramote, S., Jantra, J., Choeiphuk, C., Mingphruedhi, S., Muangkaew, P., Rungsakulkij, N., Tangtawee, P., Suragul, W., Farquharson, W. V., Wongprasert, K., Chutipongtanate, S., Sanvarinda, P., Ponpuak, M., Poungvarin, N., Janvilisri, T., ... Tohtong, R. (2024). Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation. Pharmaceuticals, 17(2), 197. https://doi.org/10.3390/ph17020197